NeuroProtectionLab

GT1 Coordinator

training

Thesis in progress

Microglia-based therapeutic strategies for Alzhiemer’s disease and related tauopathies.

See thesis »

March 16, 2022

Development of multifunctional compounds for Alzheimer’s disease.

See thesis »

March 16, 2022

Impacto de la hipertensión arterial y la diabetes mellitus tipo 2 en la enfermedad de Alzheimer: inducción de la vía de señalización keap1-NRF2 como estrategia terapéutica dirigida a factores fisiopatológicos comunes.

See thesis »

March 16, 2022

Interacción microglia-astrocito en la progresión de la taupatía: en búsqueda de nuevas dianas.

See thesis »

March 16, 2022

Defended thesis

Microglial heme oxygenase 1 (HO-1) modulation for the treatment of age-related diseases.

See thesis »

March 16, 2022

The coming of age of selective types of autophagy for the treatment of Alzheimer´s disease and related tauopathies

See thesis »

March 16, 2022

Novel Nrf2 inducers with multitarget activities for the treatment of neurodegenerative diseases.

See thesis »

March 16, 2022

Master's Thesis

Evaluation of the anti-neuroinflammatory effects of compound CH213. Lucía Viqueira-Diaz Alejo. July 2021. NRF in Alzheimer´s disease: Update on current pharmacological approaches to induce NRF2 activity. Marcos Martínez. July 2020. Pharmacological characterization of melatonin and resveratrol derivatives for potential Alzheimer’s Disease treatments. Eric del Sastre López. September 2019. Multitarget compounds for the treatment of Alzheimer’s disease. José Lombardía Gutiérrez. September 2018. NOX4 contribution in a neurodegenerative tauopathy model. Paula Trigo Alonso. September 2017.

NeuroProtectionLab is a consolidated group of the Universidad Autónoma de Madrid.

We are located in Laboratory 3 of the Department of Pharmacology and Therapeutics, Faculty of Medicine, Universidad Autónoma de Madrid.